https://pharmadevicenews.com/guardian-pharmacy-services-has-made-another-tennessee-acquisition-but-can-its-local-first-model-sustain-national-growth/ PharmaDeviceNews en 2026-11-03T07:09:31+00:00 Guardian Pharmacy Services has made another Tennessee acquisition, but can its local-first model sustain national growth? David Brown, Emily Haskins, Guardian Pharmacy Services Inc., Martin, Mike Swaim, Nautilus Pharmacy, Tennessee, Van's Institutional Pharmacy, Wellness Concepts, Zach Delaney https://pharmadevicenews.com/wp-content/uploads/2025/12/pharmadevicenews-1.png https://pharmadevicenews.com/aarvik-therapeutics-advances-arr-002-into-phase-1-and-licenses-two-adc-candidates-to-laurus-labs-for-india/ PharmaDeviceNews en 2026-11-03T07:06:25+00:00 Aarvik Therapeutics advances ARR-002 into Phase 1 and licenses two ADC candidates to Laurus Labs for India Aarvik Therapeutics, AQUALINK, ARR-002, ArriVent BioPharma, AV-P138-ADC, Jagath Reddy Junutula, Laurus Labs Limited, MUTTA, San Diego, Satyanarayana Chava, Shanghai Allist Pharmaceuticals https://pharmadevicenews.com/wp-content/uploads/2025/12/pharmadevicenews-1.png https://pharmadevicenews.com/blackstone-and-boston-scientific-strike-455m-vitalyst-deal-targeting-cardiogenic-shock-treatment-by-2030/ PharmaDeviceNews en 2026-11-03T07:03:02+00:00 Blackstone and Boston Scientific strike $455m VITALYST deal targeting cardiogenic shock treatment by 2030 Abiomed, Blackstone Inc., Blackstone Life Sciences, Boston Scientific Corporation, DanGer Shock, Impella, Johnson & Johnson, Mike Mahoney, Nicholas Galakatos, VITALYST https://pharmadevicenews.com/wp-content/uploads/2025/12/pharmadevicenews-1.png https://pharmadevicenews.com/mirum-pharmaceuticals-prepares-new-brelovitug-volixibat-and-livmarli-data-for-aasld-2026/ PharmaDeviceNews en 2026-11-03T04:08:24+00:00 Mirum Pharmaceuticals prepares new brelovitug, volixibat and LIVMARLI data for AASLD 2026 American Association for the Study of Liver Diseases, AZURE-1, brelovitug, Chris Peetz, Denver, EXPAND, LIVMARLI, maralixibat, Mirum Pharmaceuticals Inc., VISTAS, Volixibat https://pharmadevicenews.com/wp-content/uploads/2026/11/Mirums-Rare-Liver-Disease-Breakthroughs-e1793678831865.webp https://pharmadevicenews.com/gileads-weekly-hiv-pill-has-passed-phase-3-but-can-fewer-doses-deliver-better-treatment-adherence/ PharmaDeviceNews en 2026-11-03T04:03:04+00:00 Gilead’s weekly HIV pill has passed Phase 3, but can fewer doses deliver better treatment adherence? ARTISTRY, BIKTARVY, Bixlenvo, Gilead Sciences Inc., HIV Glasgow, islatravir, ISLEND, Jared Baeten, Lenacapavir, Merck & Co., PURPOSE 5, Yeytuo, Yeztugo https://pharmadevicenews.com/wp-content/uploads/2026/11/Gilead-HIV-Glasgow-2026-Research-Briefing-e1793678515393.webp https://pharmadevicenews.com/heartbeam-3d-ecg-achieves-81-8-specificity-in-132-patient-heart-attack-study-beating-standard-ecg-on-one-measure/ PharmaDeviceNews en 2026-11-03T03:58:54+00:00 HeartBeam 3D ECG achieves 81.8% specificity in 132-patient heart attack study, beating standard ECG on one measure ALIGN-ACS, Belgrade, Branislav Vajdic, Graham Nichol, HeartBeam Inc., Serbia, Transcatheter Cardiovascular Therapeutics, United States Food and Drug Administration, University of Washington https://pharmadevicenews.com/wp-content/uploads/2026/11/HeartBeams-Promising-ACS-Pilot-Data-e1793678269289.webp https://pharmadevicenews.com/nasal-foralumab-reduces-brain-inflammation-marker-in-phase-2a-multiple-sclerosis-trial/ PharmaDeviceNews en 2026-11-03T02:32:44+00:00 Nasal foralumab reduces brain inflammation marker in Phase 2a multiple sclerosis trial Brigham and Women's Hospital, Foralumab, Harvard Medical School, INFORM-MS, Mass General Brigham, Tiziana Life Sciences https://pharmadevicenews.com/wp-content/uploads/2026/11/Multiple-sclerosis-research-e1793672821974.webp https://pharmadevicenews.com/huntingtons-disease-treatment-milestone-uniqure-secures-priority-fda-review-for-one-time-gene-therapy/ PharmaDeviceNews en 2026-11-02T20:05:07+00:00 Huntington’s disease treatment milestone: uniQure secures priority FDA review for one-time gene therapy AMT-130, Enroll-HD, Huntington's disease, ifezuntirgene inilparvovec, U.S. Food and Drug Administration, uniQure https://pharmadevicenews.com/wp-content/uploads/2026/11/Gene-therapy-research-e1793649589897.webp https://pharmadevicenews.com/urologic-design-raises-1-2m-to-advance-patented-male-incontinence-device-towards-first-human-trial/ PharmaDeviceNews en 2026-11-02T16:12:47+00:00 Urologic Design raises $1.2m to advance patented male incontinence device towards first human trial Angel Investor Forum, Branford, Connecticut Innovations, David Hesse, Haven Founders Fund, HBS Alumni Angels of Boston, Matthew Stannard, Urologic Design, Yale Angels, Yale School of Medicine https://pharmadevicenews.com/wp-content/uploads/2026/11/Pharma-Device-News_-Urologic-Innovation-e1793635846604.webp https://pharmadevicenews.com/egnite-and-pathway-labs-launch-fda-cleared-ecg-ai-pilot-at-stamford-health-to-improve-structural-heart-disease-detection/ PharmaDeviceNews en 2026-11-02T16:05:48+00:00 Egnite and Pathway Labs launch FDA-cleared ECG AI pilot at Stamford Health to improve structural heart disease detection Arzhang Fallahi, CardioCare, Columbia University, Connecticut, David Hsi, EchoNext, Edwards Lifesciences, Egnite, NewYork-Presbyterian, Pathway Labs, Pierre Elias, Stamford Health https://pharmadevicenews.com/wp-content/uploads/2026/11/ECG-AI-Advances-Heart-Care-e1793635487972.webp https://pharmadevicenews.com/abbotts-sonicforce-recorded-just-0-3-lesion-failure-but-can-it-challenge-shockwave-in-coronary-calcium-treatment/ PharmaDeviceNews en 2026-11-02T16:00:01+00:00 Abbott’s SonicForce recorded just 0.3% lesion failure, but can it challenge Shockwave in coronary calcium treatment? Abbott Laboratories, American College of Cardiology, Beth Israel Deaconess Medical Center, Eric Secemsky, Johnson & Johnson, San Diego, Shockwave Medical, SonicForce, TECTONIC https://pharmadevicenews.com/wp-content/uploads/2026/11/Abbott-SonicForce-TECTONIC-Study-Infographic-e1793635087344.webp https://pharmadevicenews.com/johnson-johnson-presents-new-impella-data-following-negative-chip-bcis3-trial/ PharmaDeviceNews en 2026-11-02T05:25:17+00:00 Impella registries show better survival than CHIP-BCIS3, but can Johnson & Johnson explain the conflicting evidence? Abiomed, CHIP-BCIS3, Impella, Johnson & Johnson, Matthias Bossard, Navin Kapur, New England Journal of Medicine, PROTECT III, PROTECT IV, Transcatheter Cardiovascular Therapeutics, TRI-GUARD-PCI, Vasileios Panoulas https://pharmadevicenews.com/wp-content/uploads/2026/11/Neon-Impella-PCI-Medical-News-Infographic-e1793597314246.webp https://pharmadevicenews.com/reflow-medical-reports-zero-major-cardiac-events-at-one-year-in-nine-patient-spur-elute-study/ PharmaDeviceNews en 2026-11-02T04:14:03+00:00 Reflow Medical reports zero major cardiac events at one year in nine-patient Spur Elute study Beth Israel Deaconess Medical Center, DEEPER CORONARY, Harvard Medical School, Kathleen Kearney, Reflow Medical Inc., Scott Harding, Spur Elute, Transcatheter Cardiovascular Therapeutics, Wellington Hospital https://pharmadevicenews.com/wp-content/uploads/2026/11/Reflow-Medical-Spur-Elute-Pilot-Data-e1793592603331.webp https://pharmadevicenews.com/ge-healthcare-unveils-allia-celeo-ai-guided-interventional-system-with-european-ce-marking/ PharmaDeviceNews en 2026-11-02T04:06:37+00:00 GE HealthCare unveils Allia Celeo AI-guided interventional system with European CE marking Allia Celeo, Allia Moveo, GE HealthCare Technologies Inc., Jyoti Gera, Kat Davis, OnWatch Predict, San Diego, Transcatheter Cardiovascular Therapeutics https://pharmadevicenews.com/wp-content/uploads/2026/11/Pharma-Device-News_-AI-Imaging-Revolution-e1793592326660.webp https://pharmadevicenews.com/altruist-biologics-secures-nmpa-priority-review-for-localised-production-of-multinational-clients-biologic/ PharmaDeviceNews en 2026-11-02T03:28:10+00:00 Altruist Biologics secures NMPA priority review for localised production of multinational client’s biologic Altruist Biologics, China, Hangzhou, Innovent Biologics, Kaisong Zhou, National Medical Products Administration, Suzhou https://pharmadevicenews.com/wp-content/uploads/2026/08/PDN-tablets-generic-e1788149113473.webp https://pharmadevicenews.com/neurosense-reported-a-7-92-point-als-function-gap-with-primec-but-will-its-phase-3-trial-confirm-a-real-treatment-benefit/ PharmaDeviceNews en 2026-11-01T17:40:55+00:00 NeuroSense reported a 7.92-point ALS function gap with PrimeC, but will its Phase 3 trial confirm a real treatment benefit? Alon Ben-Noon, Harvard Medical School, Health Canada, JAMA Neurology, Massachusetts General Hospital, Merit Cudkowicz, NEALS, NeuroSense Therapeutics, PARADIGM, PARAGON, PrimeC, Shiran Zimri https://pharmadevicenews.com/wp-content/uploads/2025/12/pharmadevicenews-1.png https://pharmadevicenews.com/laplace-interventional-is-taking-on-an-approved-tricuspid-valve-with-triumph-but-can-its-new-implant-deliver-better-outcomes/ PharmaDeviceNews en 2026-11-01T17:37:14+00:00 Laplace Interventional is taking on an approved tricuspid valve with TRIUMPH, but can its new implant deliver better outcomes? Ballad Health, Edwards Lifesciences, EVOQUE, Kingsport, Laplace Interventional, Mayo Clinic, Oklahoma Heart Institute, Transcatheter Cardiovascular Therapeutics, TRIUMPH, Tulsa, Vanderbilt University Medical Center https://pharmadevicenews.com/wp-content/uploads/2026/11/TRIUMPH-Tricuspid-Valve-Trial-News-Graphic-e1793554581270.webp https://pharmadevicenews.com/eisai-is-about-to-reveal-five-years-of-lecanemab-treatment-data-but-will-long-term-therapy-justify-its-benefits-and-risks/ PharmaDeviceNews en 2026-11-01T14:34:34+00:00 Eisai is about to reveal five years of lecanemab treatment data, but will long-term therapy justify its benefits and risks? Alzheimer’s disease, Biogen Inc., Boston, Clarity AD, CTAD 2026, Eisai Co., LEADER, lecanemab, LEQEMBI, Leqembi Iqlik, Ltd. https://pharmadevicenews.com/wp-content/uploads/2026/11/Alzheimers-Drug-Data-Infographic-e1793543623687.webp https://pharmadevicenews.com/glenmark-pharmaceuticals-opens-160000-sq-ft-us-distribution-hub-serving-321-locations-across-43-states/ PharmaDeviceNews en 2026-11-01T14:28:03+00:00 Glenmark Pharmaceuticals opens 160,000 sq ft US distribution hub serving 321 locations across 43 states Allentown, Elmwood Park, Glenmark Pharmaceuticals Inc. USA, Glenmark Pharmaceuticals Limited, Lehigh Valley, Monroe, North Carolina, Pennsylvania https://pharmadevicenews.com/wp-content/uploads/2026/11/Glenmarks-Allentown-Distribution-Hub-e1793543162694.webp https://pharmadevicenews.com/eli-lilly-just-lifted-its-2026-sales-outlook-by-5-5bn-but-can-surging-glp-1-demand-keep-outrunning-price-pressure/ PharmaDeviceNews en 2026-11-01T14:18:48+00:00 Eli Lilly just lifted its 2026 sales outlook by $5.5bn, but can surging GLP-1 demand keep outrunning price pressure? AtaiBeckley, Eli Lilly and Company, Foundayo, Jardiance, Merida Biosciences, Mounjaro, Onswik, retatrutide, Zepbound https://pharmadevicenews.com/wp-content/uploads/2026/11/Eli-Lilly-Raises-2026-Guidance-e1793542613985.webp